Ovid Therapeutics (NASDAQ:OVID) Cut to “Sell” at Wall Street Zen

Posted by Francis Steltz on Jul 28th, 2026

Wall Street Zen downgraded shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

OVID has been the subject of several other research reports. Roth Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Ovid Therapeutics in a research note on Thursday, May 14th. B. Riley Financial reissued a “buy” rating on shares of Ovid Therapeutics in a research report on Tuesday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Ovid Therapeutics in a report on Friday, July 17th. Wedbush reissued an “outperform” rating and issued a $7.00 price target on shares of Ovid Therapeutics in a report on Wednesday, April 15th. Finally, HC Wainwright upped their price objective on shares of Ovid Therapeutics from $2.00 to $4.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.12.

Check Out Our Latest Stock Report on OVID

Ovid Therapeutics Stock Performance

Shares of OVID stock opened at $2.35 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 10.17 and a quick ratio of 10.17. The stock has a market cap of $438.60 million, a PE ratio of -8.10 and a beta of 0.18. The stock has a 50-day moving average of $2.46 and a 200-day moving average of $2.22. Ovid Therapeutics has a one year low of $0.47 and a one year high of $3.11.

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). Ovid Therapeutics had a negative net margin of 240.11% and a negative return on equity of 22.51%. As a group, sell-side analysts expect that Ovid Therapeutics will post -0.5 earnings per share for the current year.

Institutional Trading of Ovid Therapeutics

Large investors have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new stake in Ovid Therapeutics during the 1st quarter worth approximately $23,732,000. RA Capital Management L.P. acquired a new position in shares of Ovid Therapeutics in the fourth quarter valued at approximately $17,464,000. Affinity Asset Advisors LLC increased its position in shares of Ovid Therapeutics by 48.8% during the first quarter. Affinity Asset Advisors LLC now owns 10,636,318 shares of the company’s stock worth $23,613,000 after acquiring an additional 3,486,318 shares in the last quarter. ADAR1 Capital Management LLC increased its position in shares of Ovid Therapeutics by 6.0% during the first quarter. ADAR1 Capital Management LLC now owns 4,544,113 shares of the company’s stock worth $10,088,000 after acquiring an additional 259,113 shares in the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in shares of Ovid Therapeutics during the fourth quarter worth $6,985,000. 72.24% of the stock is owned by institutional investors.

Ovid Therapeutics Company Profile

(Get Free Report)

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.